Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...

The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to $94.31 / share. This is an increase of 21.89% from the prior estimate of ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...

GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 candidate, ...

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and ...

Structure Therapeutics (GPCR) has drawn attention after recent share price swings, including a month return of a 27.7% decline and a past 3 months gain of 80.8%, prompting investors to reassess its ...